Advanced

Two new routes to make blood: Hematopoietic specification from pluripotent cell lines vs. reprogramming of somatic cells.

Singbrant, Sofie LU ; van Galen, Peter; Lucas, Daniel; Challen, Grant; Rossi, Derrick J and Daley, George Q (2015) In Experimental Hematology 43(9). p.756-759
Abstract
Transplantation of hematopoietic stem cells (HSCs) to treat hematological disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirement of finding HLA-matched donors, as well as attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSC remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18(th) 2015, Dr. George Q Daley and Dr. Derrick J Rossi, two pioneers in the field, presented and discussed... (More)
Transplantation of hematopoietic stem cells (HSCs) to treat hematological disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirement of finding HLA-matched donors, as well as attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSC remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18(th) 2015, Dr. George Q Daley and Dr. Derrick J Rossi, two pioneers in the field, presented and discussed their most recent research on these topics in a webinar organized by the International Society for Experimental Hematology (ISEH). Here we summarize these seminars, and discuss the possibilities and challenges of the field of hematopoietic specification. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Experimental Hematology
volume
43
issue
9
pages
756 - 759
publisher
Elsevier
external identifiers
  • pmid:26143581
  • wos:000361417200002
  • scopus:84940030328
ISSN
1873-2399
DOI
10.1016/j.exphem.2015.05.007
language
English
LU publication?
yes
id
e7975318-4981-49d3-b324-ee7fa02c1cf0 (old id 7750698)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26143581?dopt=Abstract
date added to LUP
2015-08-06 22:26:44
date last changed
2017-03-23 08:52:22
@article{e7975318-4981-49d3-b324-ee7fa02c1cf0,
  abstract     = {Transplantation of hematopoietic stem cells (HSCs) to treat hematological disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirement of finding HLA-matched donors, as well as attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSC remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18(th) 2015, Dr. George Q Daley and Dr. Derrick J Rossi, two pioneers in the field, presented and discussed their most recent research on these topics in a webinar organized by the International Society for Experimental Hematology (ISEH). Here we summarize these seminars, and discuss the possibilities and challenges of the field of hematopoietic specification.},
  author       = {Singbrant, Sofie and van Galen, Peter and Lucas, Daniel and Challen, Grant and Rossi, Derrick J and Daley, George Q},
  issn         = {1873-2399},
  language     = {eng},
  number       = {9},
  pages        = {756--759},
  publisher    = {Elsevier},
  series       = {Experimental Hematology},
  title        = {Two new routes to make blood: Hematopoietic specification from pluripotent cell lines vs. reprogramming of somatic cells.},
  url          = {http://dx.doi.org/10.1016/j.exphem.2015.05.007},
  volume       = {43},
  year         = {2015},
}